An Evaluation of Three Signal-Detection Algorithms Using a Highly Inclusive Reference Event Database
暂无分享,去创建一个
David Madigan | Manfred Hauben | A. Lawrence Gould | Stephanie J. Reisinger | Donald J. O'Hara | D. Madigan | M. Hauben | A. Gould | Alan M. Hochberg | Ronald K. Pearson | Donald J. O’Hara | David I. Goldsmith | A. Hochberg | D. Goldsmith
[1] Joseph M. Tonning,et al. Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.
[2] A. B. Prasad,et al. British National Formulary , 1994 .
[3] J. Venulet,et al. Standardized assessment of drug-adverse reaction associations--rationale and experience. , 1980, International journal of clinical pharmacology, therapy, and toxicology.
[4] Manfred Hauben,et al. Trimethoprim-induced hyperkalaemia -- lessons in data mining. , 2004, British journal of clinical pharmacology.
[5] Stephanie J. Reisinger,et al. Using Data Mining to Predict Safety Actions from FDA Adverse Event Reporting System Data , 2007 .
[6] William DuMouchel,et al. Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .
[7] S. Evans,et al. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports , 2001, Pharmacoepidemiology and drug safety.
[8] M. Lindquist,et al. A Retrospective Evaluation of a Data Mining Approach to Aid Finding New Adverse Drug Reaction Signals in the WHO International Database , 2000, Drug safety.
[9] J. Reynolds. Martindale : the extra pharmacopoeia , 1972 .
[10] Darcy Wolfman,et al. Satisfaction of search in osteoradiology. , 2000, AJR. American journal of roentgenology.
[11] A Lawrence Gould,et al. Practical pharmacovigilance analysis strategies. , 2003, Pharmacoepidemiology and drug safety.
[12] M. Lindquist,et al. Signal Selection and Follow-Up in Pharmacovigilance , 2002, Drug safety.
[13] M. Hauben,et al. Time‐to‐Signal Comparison for Drug Safety Data‐Mining Algorithms vs. Traditional Signaling Criteria , 2009, Clinical pharmacology and therapeutics.
[14] E. Brown,et al. The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.
[15] D. Greenblatt,et al. A method for estimating the probability of adverse drug reactions , 1981, Clinical pharmacology and therapeutics.
[16] D. Madigan,et al. The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.
[17] Robert Ball,et al. Effects of Stratification on Data Mining in the US Vaccine Adverse Event Reporting System (VAERS) , 2008, Drug safety.
[18] J. Aronson,et al. Gold Standards in Pharmacovigilance , 2006 .
[19] L Lasagna,et al. Toward the operational identification of adverse drug reactions , 1977, Clinical pharmacology and therapeutics.
[20] Manfred Hauben,et al. Safety Related Drug-Labelling Changes , 2004, Drug safety.
[21] Communication of findings in pharmacovigilance: use of the term “signal” and the need for precision in its use , 2005, European Journal of Clinical Pharmacology.
[22] Jeffrey K Aronson,et al. Anecdotes as evidence , 2003, BMJ : British Medical Journal.
[23] Manfred Hauben,et al. Signal detection in pharmacovigilance: empirical evaluation of data mining tools , 2005, Pharmacoepidemiology and drug safety.
[24] Manfred Hauben,et al. What Counts in Data Mining? , 2006, Drug safety.